Beneficial Effects of Cannabis on Blood Brain Barrier Function in HIV Ronald J Ellis 1 , Scott Peterson 2 , Mariana Cherner 1 , Erin Morgan 1 , Rachel Schrier 1 , Bin Tang 1 , Martin Hoenigl 1 , Scott Letendre 1 , Jenny Iudicello 1 Clinical infectious diseases, 2020 Apr 16, ciaa437. Doi : 10.1093/cid/ciaa437 Abstract Background: HIV infection leads to blood-brain barrier (BBB) dysfunction that does not resolve despite viral suppression on antiretroviral therapy and is associated with adverse clinical outcomes. In preclinical models, cannabis restores BBB integrity. Methods: We studied people with HIV (PWH) and HIV- individuals who had used cannabis [...]
Lire la suiteBeta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain Esraa Aly, Maitham A. Khajah and Willias Masocha Molecules, 2020, 25, 106; doi:10.3390/molecules25010106 Abstract : Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs), therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available drugs. Smoked cannabis was reported to relieve HIV-associated neuropathic pain in clinical trials. Some constituents of cannabis (Cannabis sativa) activate cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. However, activation of the CB1 receptor is associated with side eects such as psychosis and physical dependence. Therefore, we investigated the effect of B-caryophyllene (BCP), [...]
Lire la suite